Rocket Pharmaceu Stock Price, News & Analysis

Rocket Pharmaceuticals (NASDAQ: RCKT) reported its Q4 and full-year 2024 financial results, highlighting significant progress in its gene therapy pipeline. The company's cash position stands at $372.3 million, providing runway into Q3 2026.

Key developments include ongoing dosing in the Phase 2 pivotal study of RP-A501 for Danon disease, with program updates expected in H1 2025. Long-term data from the Phase 1 study showed sustained efficacy up to five years. The company completed enrollment in the low-dose cohort of RP-A601 for PKP2-ACM, with initial data expected in H1 2025.

Financial results show R&D expenses decreased to $171.2 million from $186.3 million in 2023, while G&A expenses increased to $102.0 million from $73.3 million. Net loss was $258.7 million ($2.73 per share) compared to $245.6 million ($2.92 per share) in 2023. The company raised $182.5 million through a public offering in December 2024.

Rocket Pharmaceuticals (NASDAQ: RCKT), a late-stage biotechnology company focused on genetic therapies for rare disorders, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Gaurav Shah, M.D., the company's CEO, will deliver a presentation on Monday, January 13, at 3:45 p.m. PT and will be available for investor meetings throughout the conference.

The presentation will be accessible via webcast and will be made available on the company's website in the Investors section. Rocket Pharmaceuticals specializes in developing sustainable pipeline solutions for rare disorders with high unmet medical needs.

Rocket Pharmaceuticals (NASDAQ: RCKT) has announced the pricing of an upsized public offering of 13,200,000 shares of common stock at $12.50 per share. The offering is expected to generate gross proceeds of $165 million before deducting underwriting costs and expenses. The company has granted underwriters a 30-day option to purchase up to an additional 1,980,000 shares. The offering is anticipated to close around December 12, 2024. Morgan Stanley, Leerink Partners, and Cantor are serving as joint book-running managers, with LifeSci Capital acting as lead manager.

Rocket Pharmaceuticals (NASDAQ: RCKT), a late-stage biotechnology company focused on genetic therapies for rare disorders, has announced plans for a $150 million public offering of common stock. The company will grant underwriters a 30-day option to purchase up to an additional 15% of shares. Morgan Stanley, Leerink Partners, and Cantor are serving as joint book-running managers, with LifeSci Capital as lead manager.

The offering will be conducted through a previously filed shelf registration statement with the SEC. The final terms and completion of the offering are subject to market conditions.

Rocket Pharmaceuticals (NASDAQ: RCKT), a late-stage biotechnology company focused on genetic therapies for rare disorders, announced its participation in the 7th Annual Evercore HealthCONx Conference in Miami, Florida. CEO Gaurav Shah will conduct a fireside chat on Tuesday, December 3, at 1:45 p.m. ET and hold investor meetings throughout the day. The fireside chat will be accessible via webcast and will be available on the company's Investors section of their website.

Rocket Pharmaceuticals (NASDAQ: RCKT) presented long-term Phase 1 data for RP-A501 in Danon disease patients at the American Heart Association Scientific Sessions 2024. The results, also published in The New England Journal of Medicine, showed that all six evaluable patients remained alive and transplant-free, with sustained LAMP2 protein expression and ≥10% reduction in LV mass index at 12 months, maintained through follow-up of up to five years.

Key findings include cardiac LAMP2 expression in all evaluable patients, improvements in heart failure classification from NYHA Class II to Class I, significant reductions in cardiac biomarkers (84% median reduction in troponin, 57% in BNP), and enhanced quality of life scores (27-point median increase in KCCQ) at 24-54 months post-treatment.

Rocket Pharmaceuticals (NASDAQ: RCKT) announced it will present new data from its RP-A501 Phase 1 trial for Danon disease at the American Heart Association's 2024 Late-Breaking Science sessions in Chicago. The presentation, titled 'Danon Disease Phase 1 RP-A501 Results: The First Single-Dose Intravenous Gene Therapy with Recombinant Adeno-Associated Virus (AAV9:LAMP2B) for a Monogenic Cardiomyopathy,' will be delivered by Dr. Joseph Rossano from Children's Hospital of Philadelphia on November 18, 2024. The company will also host an investor webinar following the presentation.

Rocket Pharmaceuticals (NASDAQ: RCKT), a late-stage biotechnology company focused on genetic therapies for rare disorders, announced its participation in the UBS Global Healthcare Conference in Rancho Palos Verdes, CA. CEO Gaurav Shah will participate in a fireside chat on Tuesday, November 12, at 5:00 p.m. PT. The event will be accessible via webcast through the company's Investors section website.

Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q3 2024 financial results and pipeline updates. Key developments include completed enrollment in Phase 2 pivotal study of RP-A501 for Danon disease and low-dose cohort completion for RP-A601 PKP2-ACM study. The company initiated rolling BLA submission for RP-L102 and expects KRESLADI approval in 2025. Financial highlights show cash position of $235.7M expected to fund operations into 2026. R&D expenses decreased to $133.9M from $144.6M year-over-year, while G&A expenses increased to $76.6M from $51.8M. Net loss was $198.4M or $2.11 per share.